Chronic hemodialysis (HD) patients manifest anemia and atherosclerosis with associated oxidative stress. We explored whether intravenous infusion of vitamin C (VC) and/or use of vitamin E (VE)-coated dialysis membrane could palliate HD-evoked oxidative stress. Eighty patients undergoing chronic HD were enrolled and randomly assigned into four groups: HD with intravenous VC (n ¼ 20), HD with VE-coated dialyzer (n ¼ 20), HD with both (n ¼ 20), and HD with neither (n ¼ 20). We evaluated oxidative stress in blood and plasma, erythrocyte methemoglobin/ferricyanide reductase (red blood cells (RBC)-MFR) activity, plasma methemoglobin, and pro-inflammatory cytokines in these patients. All patients showed marked increases (14-fold) in blood reactive oxygen species (ROS) after HD. The types of ROS were mostly hydrogen peroxide, and in lesser amounts, O 2 KÀ and HOCl. HD resulted in decreased plasma VC, total antioxidant status, and RBC-MFR activity and increased plasma and erythrocyte levels of phosphatidylcholine hydroperoxide (PCOOH) and methemoglobin. Intravenous VC significantly palliated HD-induced oxidative stress, plasma and RBC levels of PCOOH, and plasma methemoglobin levels and preserved RBC-MFR activity. The VE-coated dialyzer effectively prevented RBCs from oxidative stress, although it showed a partial effect on the reduction of total ROS activity in whole blood. In conclusion, intravenous VC plus a VE-coated dialyzer is effective in palliating HD-evoked oxidative stress, as indicated by hemolysis and lipid peroxidation, and by overexpression of proinflammation cytokines in HD patients. Using VE-coated dialyzer per se is, however, effective in reducing lipid peroxidation and oxidative damage to RBCs.
Chronic hemodialysis (HD) patients manifest anemia and atherosclerosis with associated oxidative stress. We explored whether intravenous infusion of vitamin C (VC) and/or use of vitamin E (VE)-coated dialysis membrane could palliate HD-evoked oxidative stress. Eighty patients undergoing chronic HD were enrolled and randomly assigned into four groups: HD with intravenous VC (n ¼ 20), HD with VE-coated dialyzer (n ¼ 20), HD with both (n ¼ 20), and HD with neither (n ¼ 20). We evaluated oxidative stress in blood and plasma, erythrocyte methemoglobin/ferricyanide reductase (red blood cells (RBC)-MFR) activity, plasma methemoglobin, and pro-inflammatory cytokines in these patients. All patients showed marked increases (14-fold) in blood reactive oxygen species (ROS) after HD. The types of ROS were mostly hydrogen peroxide, and in lesser amounts, O 2 KÀ and HOCl. HD resulted in decreased plasma VC, total antioxidant status, and RBC-MFR activity and increased plasma and erythrocyte levels of phosphatidylcholine hydroperoxide (PCOOH) and methemoglobin. Intravenous VC significantly palliated HD-induced oxidative stress, plasma and RBC levels of PCOOH, and plasma methemoglobin levels and preserved RBC-MFR activity. The VE-coated dialyzer effectively prevented RBCs from oxidative stress, although it showed a partial effect on the reduction of total ROS activity in whole blood. In conclusion, intravenous VC plus a VE-coated dialyzer is effective in palliating HD-evoked oxidative stress, as indicated by hemolysis and lipid peroxidation, and by overexpression of proinflammation cytokines in HD patients. Using VE-coated dialyzer per se is, however, effective in reducing lipid peroxidation and oxidative damage to RBCs.
In patients undergoing hemodialysis (HD), the interaction of blood with non-biological materials of the extracorporeal circuit has been considered to be one main source of extra oxidative stress. The process of HD can activate polymorphonuclear leukocytes to produce proteolytic enzymes and reactive oxygen species (ROS) [1] [2] [3] in amounts that impair neighboring tissues/cells (including red blood cells (RBCs)) and evoke an inflammatory response. [1] [2] [3] [4] The majority of ROS generated from activated polymorphonuclear leukocytes is hydrogen peroxide (H 2 O 2 ), which causes subsequent lipid peroxidation and production of phosphatidylcholine hydroperoxide (PCOOH). PCOOH can be regarded as an indirect indicator of ROS and/or free-radical activity. 4 During the process of oxidative stress, RBCs are subject to membrane lipid peroxidation and susceptible to destruction. [5] [6] [7] Increased ROS can oxidize oxyhemoglobin (oxyHb) to yield H 2 O 2 and methemoglobin (metHb), 8, 9 which, in turn, leads to tissue hypoxia, 10 endothelial cell G 2 /M arrest, and apoptosis. 11 The plasma levels of proinflammatory cytokines (e.g., interleukin-1 and tumor necrosis factor-a) are significantly elevated in uremic patients on dialysis, 12 and the expression can be augmented further even after a single dialysis session. 13 Increased oxidative stress and a proinflammatory condition in HD patients have been shown to be related to malnutrition, 14 resistance to erythropoietin therapy, 15 and high mortality. 16 Furthermore, an increase in oxidized lipids and other macromolecules and proinflammatory cytokines could lead to cardiovascular events and other symptoms. 17, 18 Therefore, increased oxidative stress and proinflammatory cytokines are important targets for nutritional and pharmacologic therapy in uremic patients undergoing HD.
Vitamin C (VC) is more effective than vitamin E (VE), when administered intravenously, by scavenging plasma H 2 O 2 activity and reducing extracorporeal system-enhanced proinflammatory mediators. 4 VE, however, can be coated on the dialysis membrane and has been shown to exert a sitespecific scavenging effect on ROS. [19] [20] [21] Using a VE-coated dialysis membrane has also been shown to improve the immune function of leukocytes in patients undergoing extracorporeal dialysis. [19] [20] [21] In the present study, we examined the immediate effects of VE-coated dialysis membrane with or without simultaneous intravenous infusion of VC on palliating HD-evoked oxidative stress, as indicated by hemolysis and lipid peroxidation, in patients with end-stage renal disease (ESRD). Moreover, we determined their longterm effects on palliating the overexpression of proinflammatory cytokines.
RESULTS

HD activated blood and enhanced ROS formation from the blood
In the N group (HD with neither intravenous VC nor VEcoated dialyzer), an average 14-fold increase in blood ROS activity was noted in patients who underwent HD. Administration of VC could effectively suppress most of the ROS formation by 86710% in the VC (HD with intravenous vitamin C) and VCE (HD with intravenous vitamin C plus VE-coated dialyzer) groups (Figures 1a and b) . The use of VE-coated dialyzer also displayed a significant effect (50%) on palliating the ROS production in the post-HD patients.
Post-HD blood samples obtained from the N group were used for examining the effects of several antioxidants. The augmented blood ROS counts were greatly inhibited by an H 2 O 2 scavenger, catalase (by 7178%), and partially depressed by superoxide dismutase (1574%) and epigallocatechin-3-gallate (1473%) (Figure 1b) .
During an HD course in the N group, the plasma H 2 O 2 activity was gradually increased and reached a peak at 2-4 h of HD treatment. The enhanced plasma H 2 O 2 activity was inhibited by intravenous VC, but not by the VE-coated dialyzer (Figure 1c ).
Intravenous VC, not VE-coated dialyzer, increased total antioxidant status In the N group, the post-HD plasma VC and total antioxidant status (TAS) levels were significantly decreased ( Figure 2 ). This indicates that HD can cause acute oxidative stress and acute loss of plasma VC. In the VC and VCE groups, intravenous VC effectively preserved the plasma TAS levels in patients receiving HD. In agreement with the above results of mild antioxidant activity, patients for whom the VE-coated dialyzer (VE group) was used did not seem to have restored plasma TAS levels. In all four groups, there was no significant change in plasma VE and oxalate concentrations, the latter finding suggesting a minimal adverse side effect of VC.
Intravenous VC reduced HD-triggered reference H 2 O 2 formation Figure 3a shows a typical chemiluminescence emission from reference H 2 O 2 (RH 2 O 2 ) in the pre-and post-HD plasma samples from the four groups of patients. The chemiluminescence count read at E max was expressed as RH 2 
VC as well as VE-coated dialyzer inhibited HD-triggered PCOOH formation
In our studies, a single session of HD did not affect the levels of lipid profiles in any of the patients (data not shown). The baseline level of pre-HD plasma PCOOH and erythrocyte membrane PCOOH was similar among the four groups of patients. However, in the N group, the post-HD plasma PCOOH (110712 pmol/ml; Figure 3c ) and post-HD erythrocyte membrane PCOOH levels (259725 pmol/ml; Figure 3d ) were significantly (Po0.05) increased after HD. Intravenous VC significantly (Po0.05) prevented increases in post-HD plasma PCOOH (5878 vs 110712 pmol/ml in the N group; Figure 3c ) and in post-HD RBC membrane PCOOH levels (165721 vs 259725 pmol/ml in the N group; Figure 3d ). In the VE group, the VE-coated dialyzer also decreased the increase in post-HD plasma PCOOH level (83711 vs 110712 pmol/ml in the N group). On the other hand, the VE-coated dialyzer also prevented the increase in post-HD RBC membrane PCOOH levels (190720 vs 259725 pmol/ml in the N group). In the VCE group, intravenous VC and the VE-coated dialyzer in combination significantly reduced post-HD plasma PCOOH (4977 vs 110712 pmol/ml in the N group, Po0.05) and post-HD RBC membrane PCOOH levels (154720 vs 259725 pmol/ml in the N group, Po0.05).
Both VC and VE reduced HD-triggered metHb formation
A single session of HD inhibited the activities of NADHmetHb reductase (NADH: nicotinamide adenine dinucleotide (reduced form)) and NADH-ferricyanide reductase in erythrocytes, and it increased plasma metHb levels ( Figure 4) . Intravenous VC or VE significantly preserved the activities of erythrocyte ferricyanide reductase and erythrocyte metHb reductase, and decreased the HD-augmented metHb level. Long-term effect of intravenous VC and VE-coated dialyzer on oxidative stress and inflammatory markers
To determine the long-term effects of HD in the VCE group of patients, we recorded the pre-HD plasma levels of RH 2 O 2 , PCOOH, TAS, and C-reactive protein (CRP) each month in the four groups of patients for 2 months. Among the four groups, there was no significant difference in the patients' clinical characteristics and in the baseline blood chemistry, including the lipid profiles.
As shown in Figure 6 , after 2 months of HD in the N group, the pre-HD plasma contained elevated levels of RH 2 O 2 (Po0.05), whereas the levels of PCOOH and CRP were only mildly increased (P40.05). The pre-HD plasma level of TAS tended to decrease (P40.05). In the VC and VCE groups, the pre-HD plasma levels of RH 2 O 2 and PCOOH were significantly decreased (Po0.05), whereas pre-HD CRP level tended to decrease (P40.05). The pre-HD TAS level was significantly (Po0.05) increased. In the VE group, all of the parameters remained stationary.
After 2 months of HD treatment, 13 plasma cytokines and two adhesion molecules that are critical to the inflammatory response, which the VCE group started with high ratios and N group started with low ratios, decreased ( Figure 7 ). As the changes in multiple cytokines levels after the 2-month intervention are statistically significant, the chance of 'regression to the mean' rather than a real effect of intervening with VC and VE is supposed to be less than 0.05. the activity of erythrocyte reductases, leading to hemolysis; and (4) increased levels of proinflammatory cytokines. Activation of polymorphonuclear leukocytes and monocytes has been described frequently during HD, accounting for the release of ROS, mostly H 2 O 2 , and cytokines. 3, 12, 13, 17, [22] [23] [24] [25] [26] Anemia, defective immunologic function, and accelerated atherosclerosis are common HD-related side effects of ESRD and may involve several inter-related processes, such as oxidative stress, endothelial dysfunction, and vascular calcification, in a milieu of constant low-grade inflammation with impaired function of neutrophils and T cells, as well as a dysregulated cytokine network. 7, 12, 13, 18, [22] [23] [24] [25] [26] We showed that intravenous VC during HD could restore the plasma TAS status and effectively alleviate ROS formation. The use of a VE-coated dialyzer had only a mild effect in reducing HD-triggered H 2 O 2 formation; however, its use is very effective in preventing lipid peroxidation and RBC damage. The combination of intravenous VC and a VEcoated dialyzer can relieve HD-evoked oxidative stress, preserve the activity of erythrocyte reductases, and inhibit the overexpression of proinflammatory cytokines during 2 months of treatment. Previously, the use of a VE-coated hemodialyzer had been shown to prevent monocyte activation, reset interleukin-12 and interleukin-18 release, and restore the tissue helper type 1/2 lymphocyte balance toward normality. 26 H 2 O 2 may cause subsequent oxidation and release of other oxidized metabolites. As a primary lipid peroxidation product from membrane phospholipids, PCOOH is distributed in the very low-density lipoprotein and low-density lipoprotein fractions 3, 4 as well as in erythrocyte membranes. The significant increases of PCOOH, metHb, and two RBC reductases (NADH-ferricyanide reductase and -metHb reductase) in post-HD plasma and RBC implicate potential RBC damage secondary to lipid peroxidation. MetHb is derived from oxyHb by autoxidation, a reaction that can be accelerated by H 2 O 2 . 27 Human oxyHb reacts with Fe(II)(CN) 5 H 2 O 3À and yields H 2 O 2 and metHb. 8 In this study, HD-triggered H 2 O 2 formation was positively correlated with the degree of hemolysis and with metHb levels.
Both VC and VE are effective in preventing RBC lipid peroxidation and oxidative damage. A VC-mediated transplasma membrane electron transport system (e.g., NADHferricyanide reductase and NADH-metHb reductase) is present on RBC and macrophage membranes. VC can donate electrons to a trans-plasma membrane electron transfer activity in erythrocytes 28 and thereby recover erythrocyte reductase activity. This system can reduce cytotoxic ferricyanide/metHb to functional ferrocyanide/oxyHb. 29, 30 Increased H 2 O 2 repressed metHb reductase expression in HeLa cells; 31 deficiency of the enzyme, an autosomal recessive trait, results in hereditary methemoglobinemia. 32 Our study showed that RBC NADH-ferricyanide reductase and NADHmetHb reductase activity was impaired after HD; however, the activity was effectively restored by VC. 3, 4 Other H 2 O 2 scavengers (e.g., catalase) have been shown to restore electron transfer activity and prevent the H 2 O 2 mediated-conversion of oxyHb to metHb. 8 Thus, the protection by VC against oxidative stress may well be related to its direct scavenging and electron transfer activity.
VE, a lipophilic chain-breaking antioxidant, delays lipid peroxidation and stabilizes the erythrocyte plasma membrane. 33, 34 Our data demonstrate that the VE-coated dialyzer led to significant decreases in plasma and erythrocyte PCOOH levels, as well as the plasma metHb level, but had no effect on the HD-enhanced H 2 O 2 level. The VE-coated dialyzer provided more effective antioxidant defense than did peroral administration of VE. 20 Our and other studies revealed that there was no significant difference in plasma VE levels between patients treated with a non-VE-coated or VE-coated dialyzer. 35 This suggests that the VE-coated dialyzer may decrease oxidative stress and lipid peroxidation through a mechanism occurring on the surface of the dialyzer, but not through a systemic antioxidant effect by VE eluted from the membrane. VC could act to protect plasma membranes against peroxidation by reduction of the a-tocopheroxyl radical to a-tocopherol and recycling of a-tocopherol in RBCs. 36, 37 ESRD patients on maintenance HD show systemic inflammation due to uremia and dialysis and suffer from rapidly progressing atherosclerosis 16, 38 and severe anemia. 39 In our study, the N group (no intervention) appeared to show a progressive increase in oxidant stress with time. It implied that the ESRD patients in the N group were not at steady state at entry to the study. Oxidative denaturation of hemoglobin and membrane lipid peroxidation render uremic RBC more sensitive to osmotic and mechanical stresses. 29 HD-augmented hemolysis has been proposed as a significant factor with regard to HD-related shortened erythrocyte survival. 29 VE supplementation for HD patients resulted in reduced erythropoietin dosage requirements. 34 HD patients with stable hemoglobin levels and not receiving erythropoietin therapy exhibited a higher hydroxyl-radical scavenging activity when compared with those in need of erythropoietin: 20 it may be argued that erythropoietin or anemiaassociated increments in the oxidant burden may be counterbalanced by a higher consumption of antioxidants like VC. Another study had shown that the dose of erythropoietin as well as the ratio of erythropoietin/hemoglobin was found to correlate positively with serum concentrations of 8-hydroxy-2 0 -deoxyguanosine, an oxidation product of DNA. 21 Pro-oxidants reduced erythropoietin synthesis in human hepatoma cells, whereas antioxidative cocktail of vitamins A, E, and C increased erythropoietin production in the kidney. [33] [34] [35] [36] [37] Inflammatory cytokines play an important role in the progression of atherosclerosis. 16 Cytokines are a heterogeneous group of polypeptide mediators that have been associated with activation of numerous functions, including the immune system and inflammatory responses. 40 Importantly, our data demonstrate that the combination of VC and a VE-coated dialyzer downregulates several proinflammatory cytokine levels during HD. These findings provide new insight into the molecular events that resolve inflammation after polymorphonuclear leukocyte activation in patients undergoing HD. VE can inhibit oxidized low density lipoprotein-induced intracellular adhesion molecule-1 and vascular cellular adhesion molecule-1 expression and decrease the influx of leukocytes in the vasculature by downregulating E-selectin expression, interleukin-1 secretion, and attenuating nuclear factor-kB activation. 41 High concentrations of VC scavenge O 2 KÀ and restore endothelium-dependent vasodilation in humans who have cardiovascular risk factors. 42 Impaired endothelial vasodilation can be improved by VC, an effect that can be reversed by the nitric oxide synthase inhibitor N(G)-monomethyl-Larginine. 43 VC prevents the interaction of O 2 KÀ and nitric oxide only at very high physiologic concentrations. 44 VC overdoses may cause secondary oxalosis via an increase in plasma oxalate levels and the deposition of calcium oxalate in various tissues. 4, 45, 46 In our study, the plasma oxalate level was not increased during a single HD session or after 2-month treatment with 1 g of intravenous VC.
In conclusion, our findings demonstrate that intravenous VC plus a VE-coated dialyzer is effective in palliating HDevoked oxidative stress, as indicated by hemolysis and lipid peroxidation, and overexpression of proinflammatory cytokines in HD patients. However, further study is mandatory for elucidation of the long-term benefits of this combination therapy with regard to erythropoietin responsiveness, morbidity, and mortality in chronic HD patients.
MATERIALS AND METHODS Patients
We enrolled 80 patients (55 males and 35 females) who had been undergoing maintenance HD at the Taipei Municipal Hoping Hospital for 1272 months. These patients had no history of habitual smoking, malignancy, inflammatory disorders, chronic or acute infections, supplementary of VC or VE, therapy with either oral or intravenous iron, or treatment with anti-inflammatory drugs during the preceding 3 months. They were randomly assigned to four groups: HD with intravenous VC (1 g in 250 ml of saline infused over 4 h of HD; VC group; n ¼ 20), HD with 250 ml of saline infusion and VE-coated dialyzer (VE group; n ¼ 20), HD with intravenous vitamin C plus VE-coated dialyzer (VCE group; n ¼ 20), and HD with neither intravenous VC nor VE-coated dialyzer treatment (N group; n ¼ 20). The VC solution (Tai-Yu Pharmaceutical, Taipei, Taiwan) was prepared in 1 g/250 ml of saline before use. A VEcoated EE18 Excerbrane s membrane (Terumo Co., Shibuyaku, Japan) was used in the VE and VCE groups, and a PSN (Polysynthane s membrane, Baxter Healthcare Co., Deerfield, IL, USA) was used in the VC and N groups.
All patients received a standardized HD prescription: bicarbonate dialysate flow, 500 ml/min; blood flow, 250-300 ml/min; 4 h per session and three sessions a week. The clearance (K t /V) in all of these patients was maintained between 1.2 and 1.5. Although there was a difference in the surface areas of the above-mentioned non-highflux dialyzers (1.8 m 2 in EE18 and 1.7 m 2 in PSN), no significant intergroup difference in K t /V was noted.
The patients had ESRD due to either diabetes (n ¼ 49) or chronic glomerulonephritis (n ¼ 31); the distributions of the two were similar in all four groups. During the 2-month experimental period, none of the patients took drugs with an established or potential oxidizing effect, and none used antioxidants such as VC or VE. This clinical trial followed the Declaration of Helsinki and was permitted by the Human Research Committee, Taipei Municipal Hoping Hospital.
Blood samples and biochemical analysis Blood (10 ml) was collected via the arterial line of the HD circuit, before the start and the end of an HD session, into a heparinized sterile test tube and was processed within 1 h. Concerning the effects of hemoconcentration during HD, the post-HD levels of various plasma biochemicals were corrected with the following equation:
The whole blood cell count, hemoglobin level, and hematocrit were determined with an autoanalyzer (Coulter STKS, Hialeah, Finland). Plasma levels of total cholesterol, triglycerides, low-density lipoprotein, very low-density lipoprotein, and high-density lipoprotein were assessed enzymatically by automated procedures. The measurement of lipoprotein(a) [Lp(a)] was performed with a commercial LPA kit (Beckman Coulter Array System, Skovlunde, Denmark). Plasma urea nitrogen and creatinine were determined with an autoanalyzer (Hitachi 736-15, Ibaraki, Japan). The plasma oxalate concentration was determined by an enzymatic method. 45 Measurement of ROS activity in whole blood and plasma To determine the ROS activity in whole blood and plasma, we sampled and isolated plasma from the four groups of patients at various time points through the first HD session of the study. After sampling, 0.2 ml of whole blood or plasma was immediately added to the luminol solution, and ROS signals were measured. 4 To identify the types of ROS in the HD-activated blood, we studied the effects of various ROS inhibitors, including superoxide dismutase (an O 2 KÀ scavenger, 30 U), catalase (an H 2 O 2 scavenger, 30 U), and epigallocatechin-3-gallate (an HOCl and H 2 O 2 scavenger, 10 mg). 4 To test the in vitro effects of VC or VE (10 mg), we compared the ROS signals in blood samples obtained from the N group before and after treatment with VC or VE.
Plasma VC and VE assay To preserve VC, an aliquot of plasma was deproteinized with 10% metaphosphoric acid (1:1, vol/vol), and the supernatant was kept at À801C. Plasma VC was measured by high-performance liquid chromatography (Hitachi D-7000 HPLC system) with UV detector at 254 nm with a Cosmosil 5C 18 -MS column (250 Â 4.6 mm ID) with a 5-mm particle size. 47 VE was measured, after extraction with ethanol and hexane, by high-performance liquid chromatography with UV detection at 292 nm 48 with a Cosmosil 5C 18 -MS column (150 Â 4.6 mm ID) with a 5-mm particle size. The system manager software (D-7000, version 3.0; Hitachi) was used for VC and VE peak integration and data acquisition.
The extraction recoveries of standards of VC and VE within the concentration range of the assay were 87 and 98%. For VC and VE, within-day variability was lower than 14.2%, whereas between-day variability did not exceed 15.2%. Within-day variability averaged 10.172.6% for VC and 5.171.3% for VE. Mean between-day variability was 10.672.7% for VC and 5.371.3% for VE.
Measurements of specific plasma antioxidant activity and plasma TAS A chemiluminescence method for evaluation of specific antioxidant activity of RH 2 O 2 in the tested plasma was well established in our laboratory. 3, 4 We measured the TAS of plasma (20 ml) by a commercial kit (TAS kit, Randox, San Francisco, CA, USA) according to the manufacturer's instructions. 3, 4 Measurement of lipid peroxidation products A lipid peroxidation product, PCOOH, originating from oxidized phosphatidylcholine is a primary lipid peroxidation product 49 and was measured to serve as an indication of oxidative stress as described previously. 3, 4 The extraction recovery, within-day assay variability, and between-day assay variability were 96, 6.7, and 8.9%.
Spectrophotometric assessment of oxidized hemoglobin and RBC reductase activities HD-induced oxidative stress, via erythrocyte membrane lipid peroxidation, would lead to erythrocyte destruction and hemoglobin release. We determined the plasma concentration of metHb spectrophotometrically. 27 The hemolysis score was determined by spectrophotometric measurement at 540 nm, and with a Coulter counter (Coulter Onix, Miami, FL, USA).
A reduced activity of RBC trans-plasma membrane electron transport system, including ferricyanide reductase and metHb reductase, could lead to cell damage and increase plasma metHb and H 2 O 2 concentration. 29, 30 RBC ferricyanide reductase activity was measured as described previously. 50 MetHb reductase activity was assayed by use of 2,6-dichlorophenol indophenol as an electron acceptor. 51 NADH-metHb reductase activity is expressed as nanomoles of 2,6-dichlorophenol indophenol reduced per minute per milligram of metHb (nmol 2, 6-dichlorophenol indophenol reduced/min mg metHb).
Multiple cytokine antibody array and CRP assay Multiple cytokine expression levels were determined by use of RayBio s human cytokine protein arrays VI and VII (RayBiotech Inc., Norcross, GA, USA) according to the manufacturer's instructions. Serum CRP concentrations measured with an immunometric kit (717-80A3, Iatron Laboratories Inc., Tokyo, Japan) were determined with an autoanalyzer (Tectron U-240 Plus).
Statistical analysis
All values are expressed as mean7s.e.m. For cross-sectional data, the comparisons between the NCNE group and the other three experimental groups were performed by one-way ANOVA and post hoc analysis with the Bonferroni procedure. Within-group comparisons between pre-and post-HD values were performed by paired t-test. For longitudinal data, repeated measures ANOVA with post hoc analysis with the Bonferroni procedure were used to analyze the between-and within-group differences. Po0.05 was adopted as indicating statistical significance.
